Zymeworks (ZYME) Stock: Buy, Sell, or Hold?
ZYME - Zymeworks Inc.
$28.44
0.33 (1.16%)
▲
5d:
+10.45%
30d:
+3.42%
90d:
+24.41%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When ZYME Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ZYME shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ZYME shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.61
Based on -0.8% avg growth
INTRINSIC VALUE TODAY
$13.42
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZYME is currently trading at $28.44, which is considered extended relative to its 30-day fair value range of $25.43 to $27.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 31.5) compared to its historical average (52.7). Remarkably, the market is currently pricing in an annual earnings decline of 15.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ZYME is in a uptrend. The price is approaching resistance at $28.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZYME scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.21 (+44.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYME is in a uptrend. The price is approaching resistance at $28.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZYME scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.21 (+44.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$25.43 -
$27.17
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
Protect Your Profits
Holding ZYME? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.9% below Wall St target ($41.21)
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$25.43 -
$27.17
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$24.60
Resistance Level
$28.97
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.51
Wall Street Target
$41.21
(+44.9%)
Revenue Growth (YoY)
-90.6%
Valuation Discount vs History
-15.7% cheaper
PE vs Historical
31.5 vs 52.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.7%
(market-implied from PE analysis)
1-Year Target
$25.60
(-10%)
2-Year Target
$23.04
(-19%)
3-Year Target
$20.73
(-27%)
3-Yr Target (if PE normalizes)
(PE: 32→53)
$34.68
(+22%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.5, Growth: -5.6%)
$23.94
(+-16%)
Base:
(SPY PE: 19.9, Growth: -5.6%)
$15.09
(-47%)
Bear:
(PE: 16.9, Growth: -5.6%)
$12.83
(-55%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 31.5 to 52.7
Stabilization Target:
$47.57
(+67.3%)
PE Expansion Potential:
+67.3%
Share & Embed Analysis
Last updated: October 23, 2026 7:42 AM ET
Data refreshes hourly during market hours. Next update: 8:42 AM
Data refreshes hourly during market hours. Next update: 8:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYME showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
Advanced ZYME Option Strategies
Professional options setups generated by AI based on today's ZYME price and gamma walls.
